Europe Orthopedic Devices Market size surpassed USD 8 billion in 2020 and is anticipated to record a CAGR of around 3.7% from 2021 to 2027.
Orthopedic devices are developed to reduce or manage musculoskeletal concerns by supporting bone fixation and are used in replacing the articulating surfaces in various joints in the body. Orthopedic devices comprise of joint reconstruction devices, spinal devices, and other tailored implants & apparatus. These devices find applications in the management of multiple musculoskeletal ailments such as trauma, degenerative conditions, deformities, and encompass a broad range of diseases such as bone fracture, osteoarthritis, joint dislocation, and scoliosis among others.
Get more details on this report - Request Free Sample PDF
The growing geriatric population in the countries across Europe will fuel the orthopedic devices adoption rate. The aging population represents one of the key demographic trends that has been remarkably affecting most of the countries in the region by surging the long-term care costs associated with chronic ailments including musculoskeletal injuries. Older people representing a proportionately higher population share are anticipated to promote the use of orthopedic devices to meet the rising need for the management of musculoskeletal ailments.
Musculoskeletal conditions consist of over 150 types that distort the locomotor system and range from short-term conditions including sprains, fractures, & strains, to chronic conditions related to functioning limitations and disability. These conditions are usually accompanied by symptoms such as pain and restrictions in mobility, dexterity, and functioning, reducing the quality of life, etc. The rise in the prevalence of musculoskeletal diseases such as musculoskeletal pain, osteoarthritis, rheumatoid arthritis, osteoporosis, and gout among others are expected to have a significant impact, boosting the Europe orthopedic devices market growth.
The joint reconstruction orthopedic devices market size in Europe was over USD 3,568 million in 2020, attributed to a surging preference for minimally invasive techniques, a growing number of joint reconstruction surgeries, etc. As per the National Joint Registry, around 160,000 total hip and knee replacement surgeries are performed every year in Wales and England.
Easy accessibility to minimally invasive surgeries in the Europe region has further proven advantageous for improving the scope of demand for joint reconstruction devices. The advent of novel surgical techniques that follow different approaches aids in decreasing the traumatic conditions has impacted the business revenue significantly. The adoption of customized and patient-specific implants is increasing in countries across Europe attributed to the technological advancements in joint reconstruction devices as it provides better anatomic fit with reduced operating time, etc.
Germany orthopedic devices market accounted for more than 22% revenue share in 2020. This substantial market size is owing to the growing prevalence of orthopedic diseases, favourable government initiatives to promote musculoskeletal health in the country, and the rising geriatric population among others. Osteoarthritis is one of the ten most damaging diseases with about 80% of people with osteoarthritis face limitations in movement and over 25% cannot complete their regular activities.
Key companies operating in the Europe orthopedic devices market landscape include Waldemar LINK, TriMed Inc., Smith & Nephew, NuVasive, Microport Scientific Corporation, Integra LifeSciences, and Globus Medical.
These industry players are involved in several strategies such as collaborations, mergers, and acquisitions to maintain their market position. For instance, in April 2021, Zimmer Biomet received FDA approval for ROSA Partial Knee System for Robotically Assisted Partial Knee Arthroplasty. The system is developed for compatibility with Persona Partial Knee with a clinically proven legacy and offers patient satisfaction. This approval would help the company to expand its product portfolio.